Metástasis

IDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations

Retrieved on: 
Tuesday, October 23, 2018

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2018 /PRNewswire/ --IDEAYA Biosciences, Inc., has entered into an exclusive license agreement with Novartis to develop and commercialize Novartis' LXS196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment of cancers with GNAQ and GNA11 mutations.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 23, 2018 /PRNewswire/ --IDEAYA Biosciences, Inc., has entered into an exclusive license agreement with Novartis to develop and commercialize Novartis' LXS196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment of cancers with GNAQ and GNA11 mutations.
  • MUM is an orphan disease of high unmet medical need, with median overall survival of approximately 10 months and no FDA approved therapies.
  • IDEAYA will continue development in metastatic uveal melanoma and will also explore a tumor agnostic basket study of solid tumors with mutations of GNAQ and GNA11.
  • Notably, approximately 90% of metastatic uveal melanoma patients harbor activating mutations in GNA11 or GNAQ.

MBC Connect Empowers Metastatic Breast Cancer Community with New Mobile App to Leverage Patient Data and Drive Research

Retrieved on: 
Saturday, October 13, 2018

NEW YORK, Oct. 13, 2018 /PRNewswire/ --Today, the Metastatic Breast Cancer Alliance launched MBC ConnectTM, a free mobile and web-based tool for patients with metastatic breast cancer (MBC) that will build a powerful database of patient information to help drive research, discoveries, and advances for the MBC community.

Key Points: 
  • NEW YORK, Oct. 13, 2018 /PRNewswire/ --Today, the Metastatic Breast Cancer Alliance launched MBC ConnectTM, a free mobile and web-based tool for patients with metastatic breast cancer (MBC) that will build a powerful database of patient information to help drive research, discoveries, and advances for the MBC community.
  • MBC Connect provides access to an interactive patient registry and a research portal with opportunities to explore de-identified patient data.
  • "MBC Connect is designed to address some very serious challenges in the MBC community," said Marc Hurlbert, Chairman, MBC Alliance.
  • MBC (or stage IV breast cancer) is defined as when cancer has spread beyond the breast to other organs in the body, most often bones, lungs, liver, or the brain.

Metastatic Breast Cancer (MBC) Alliance Announces the Election of Shirley Mertz as the new Chair and Christine Benjamin as Vice Chair

Retrieved on: 
Wednesday, October 3, 2018

Both Mertz and Benjamin are founding members and have been active members of the MBC Alliance.

Key Points: 
  • Both Mertz and Benjamin are founding members and have been active members of the MBC Alliance.
  • Shirley Mertz is the President of the MBC Network, a founding member of the MBC Alliance.
  • Shirley received a diagnosis of metastatic breast cancer in 2003, twelve years after being treated for DCIS.
  • Christine Benjamin, LMSW, is the Breast Cancer Program Director at SHARE, a leading patient support organization helping those diagnosed with breast or ovarian cancer.

Tri-North Builders' Fourth Annual Tequila for Ta-Tas Event Raises Metastatic Breast Cancer Awareness and Funds

Retrieved on: 
Wednesday, September 19, 2018

What often is not addressed in these campaigns is that once breast cancer metastasizes, it is incurable.

Key Points: 
  • What often is not addressed in these campaigns is that once breast cancer metastasizes, it is incurable.
  • Despite the amazing, dramatic decreases in breast cancer mortality rates overall, the statistics of metastatic breast cancer (MBC) mortality have not budged in over 30 years.
  • All proceeds will go to the UW-Madison Carbone Cancer Center's fund that directly supports Stage IV metastatic breast cancer research.
  • Anyone that has known or loved someone affected by Stage IV metastatic breast cancer knows the physical and mental suffering that ultimately results in a tragedy.

ApoCell Announces Publication of First Therapeutic Target Biomarker Correlation in Circulating Tumor Cells and Overall Survival in Patients with Solid Tumors

Retrieved on: 
Wednesday, September 19, 2018

This is the first publication to show changes in a therapeutic target biomarker detected in CTCs that impacts overall survival in an important subset of metastatic breast cancer (MBC) patients.

Key Points: 
  • This is the first publication to show changes in a therapeutic target biomarker detected in CTCs that impacts overall survival in an important subset of metastatic breast cancer (MBC) patients.
  • CTCs have long been known to exist in cancer patients' blood, with a clear correlation established between the number of CTCs and disease progression.
  • Therapeutic target biomarker expression was detected in 52%-90% of CTC samples; no significant associations with overall survival were observed in pre-treatment samples for either group.
  • Patients whose CTCs had a change from high to low biomarker expression after treatment had the greatest overall survival benefit from EP.

Propanc Biopharma Provides Shareholder Update after Presenting at the 25th Annual NewsMakers in the Biotech Industry Conference

Retrieved on: 
Wednesday, September 12, 2018

Furthermore, we discovered a key gene target for drug developers, Rac1B, which increased as a result of PRP treatment.

Key Points: 
  • Furthermore, we discovered a key gene target for drug developers, Rac1B, which increased as a result of PRP treatment.
  • This gene suppresses cellular motility and proliferation of CSCs by ultimately inhibiting TGF-, a known growth factor responsible for tumorigenesis and metastasis," said Mr. Nathanielsz.
  • Management was pleased to receive interest at the conference and is currently looking into potential financing options with its advisors and investment banking team.
  • Propanc Biopharma, Inc. (the "Company") is a biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers.

Global Metastatic Bone Disease Market 2017-2023

Retrieved on: 
Monday, September 10, 2018

The "Global Metastatic Bone Disease Market - by Treatment, Origin of Metastasis, End User, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2017-2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Metastatic Bone Disease Market - by Treatment, Origin of Metastasis, End User, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2017-2023)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Metastatic Bone Disease Market was worth 12.45 Billion USD in 2017 and it is estimated to grow to 19.86 Billion USD by 2023 with a CAGR of 8.09% between 2017 and 2023.
  • The North America is expected to have largest Global Metastatic Bone Disease Market mainly due to the developing regions such as U.S., Canada, and others.
  • The increased prevalence of cancer and investment on the drug discovery and development are the main reasons which drives growth of Global Metastatic Bone Disease Market.

Circulating Tumor Cells To Help Stage Metastatic Breast Cancer, New Research To Be Featured at ASCO Annual Meeting

Retrieved on: 
Wednesday, May 30, 2018

CTCs are cancer cells that are released and disseminated into the bloodstream and lymphatic system by advanced cancers.

Key Points: 
  • CTCs are cancer cells that are released and disseminated into the bloodstream and lymphatic system by advanced cancers.
  • A liquid biopsy uses a sample of blood to detect circulating tumor markers (i.e.
  • CELLSEARCH is the first and only clinically validated blood test cleared by the FDA for detecting and enumerating circulating tumor cells (CTCs) to help physicians manage patients with metastatic breast, prostate and colorectal cancers*.
  • To learn more about the CELLSEARCH System , ASCO annual meeting attendees can visit Menarini Silicon Biosystems at Booth #3107.

Circulating Tumor Cells To Help Stage Metastatic Breast Cancer, New Research To Be Featured at ASCO Annual Meeting

Retrieved on: 
Wednesday, May 30, 2018

CTCs are cancer cells that are released and disseminated into the bloodstream and lymphatic system by advanced cancers.

Key Points: 
  • CTCs are cancer cells that are released and disseminated into the bloodstream and lymphatic system by advanced cancers.
  • A liquid biopsy uses a sample of blood to detect circulating tumor markers (i.e.
  • CELLSEARCH is the first and only clinically validated blood test cleared by the FDA for detecting and enumerating circulating tumor cells (CTCs) to help physicians manage patients with metastatic breast, prostate and colorectal cancers*.
  • To learn more about the CELLSEARCH System , ASCO annual meeting attendees can visit Menarini Silicon Biosystems at Booth #3107.

Lustgarten-Funded Researcher Unlocks How Pancreatic Cancer Metastasizes to the Liver

Retrieved on: 
Thursday, May 17, 2018

These quiescent cancer cells in the liver don't divide, but they can be activated under certain conditions and proliferate to become clinically relevant metastases.

Key Points: 
  • These quiescent cancer cells in the liver don't divide, but they can be activated under certain conditions and proliferate to become clinically relevant metastases.
  • The team thinks solitary cancer cells have already spread to the liver in many patients well before they go to surgery to have their primary tumor removed.
  • Dr. Fearon estimates that in a typical patient, 14 million cancer cells pass through the liver every day.
  • When ER stress was blocked, the DCCs became more typical pancreatic cancer cells and were then eliminated by the immune system.